Bachem and Axon Neuroscience Sign Contract for Finished Dosage Forms of Peptide-Protein Conjugate

Bachem, the globally recognised manufacturer of the highest quality of biochemical and pharmaceutical products has entered into a collaboration with Axon Neuroscience SE. Axon is a biotech company committed to the development of disease modifying immunotherapy and early diagnostics for Alzheimer’s disease.

The collaboration will see Bachem manufacture Axon’s investigational API and supply it as a finished dosage form under Bachem’s Clinalfa® brand. Axon’s innovative product targeting Alzheimer’s disease consists of a peptide-protein conjugate and will enter phase I clinical trials in Europe.

Roman Sivak, CEO of Axon Neuroscience, comments: “We have chosen Bachem because of their stellar reputation for quality work and the wide range of services they provide, spanning from peptide API production to conjugates and fill finish activities.”

Dr. José de Chastonay, Chief Marketing Officer of Bachem, added: “Bachem is proud to have been selected as the supplier for Axon’s innovative Alzheimer product. Manufacturing a peptide-protein conjugate as well as providing finished dosage forms for clinical trials are valuable services we provide and perfectly complementary to our key expertise in peptides.”

About Bachem
Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries.

It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio.

Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides

For more information on finished dosage forms of peptide-protein conjugate, please contact Bachem directly.